This gene testing initiative is appropriate for patients suspected of having an inherited retinal disease (e.g., retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease, etc.) and who have experienced one or more of the following:
Note: This program does not test for genes associated with age-related macular degeneration.
The benefits of genetic testing include the ability to:
The Invitae Inherited Retinal Disease Panel tests approximately 300 genes for variants that are associated with IRD. Once Invitae receives the sample, you will receive results within 10 to 21 calendar days, on average.VIEW PANEL
The ID YOUR IRD program does not currently accept orders through the online portal. To place an order, download and complete the paper order form and return to Invitae via kit shipment or fax/email at (415) 276-4164 or firstname.lastname@example.org.
To collect a specimen:
To receive results:
Individuals tested through the Spark ID YOUR IRD® program will be eligible for no-charge, post-test genetic counseling to help them understand their test results. Invitae's genetic counseling services include:
Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit www.invitae.com.
Spark Therapeutics — a fully integrated, commercial company committed to discovering, developing and delivering gene therapies — challenges the inevitability of genetic diseases, including blindness, hemophilia, lysosomal storage disorders and neurodegenerative diseases. We see the path to a world where no life is limited by genetic disease. For more information, visit www.sparktx.com, and follow us on Twitter and LinkedIn.
While Spark provides financial support for this program, tests and services are performed by independent third parties. Healthcare professionals must confirm that patients meet certain criteria to use the program. In accordance with the terms and conditions of the program, patients must consent to disclose personally identifying information and genetic test results to Spark. Spark also receives contact information for healthcare professionals who consent and use this program. Genetic testing and counseling are available in the US only. Healthcare professionals who use this program have no obligation to recommend, purchase, order, prescribe, promote, administer, use or support any Spark product. Please review all terms and conditions of the program before submitting test samples.
Spark and ID YOUR IRD and its design are trademarks or registered trademarks of Spark Therapeutics, Inc. in the United States and other countries.